Tamiflu (Oseltamivir Phosphate), commonly referred to as Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B (flu). Tamiflu works by slowing the spread of flu viruses in the body. It is available as an oral capsule and is administered within 2 days of onset of symptoms. For seasonal flu, Tamiflu is prescribed for 5 days to help reduce symptoms. For pandemic flu, it may be recommended to take Tamiflu for 10 days.
The global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Tamiflu has emerged as the preferred choice of treatment amongst physicians around the world, especially during flu seasons and pandemics. It offers a convenient oral dosage form with proven efficacy against both type A and B influenza viruses. According to CDC, flu affects millions of people annually and leads to hundreds of thousands of hospitalizations in the United States. With resurgence of influenza cases post the pandemic, the demand for effective influenza medications such as Tamiflu has picked up significantly.
Market Dynamics:
Rising Influenza Cases and Growing Focus on Pandemic Preparedness
The global Tamiflu market is primarily driven by increasing prevalence of influenza infections worldwide. As per WHO, influenza causes severe illness in 3-5 million people and results in 290,000- 650,000 respiratory deaths globally each year. A strong pipeline presence with multiple generic and branded formulations is another key factor, estimated to aid the market growth over the forecast period. With pandemic preparedness gaining higher priority on the policy agenda, governments across many countries are building Tamiflu stockpiles to prevent influenza-related morbidity and mortality during pandemics. Increased uptake in both developing and developed countries is expected to spur the demand for Tamiflu during the forecast period.
Segment Analysis
The global Tamiflu (Oseltamivir Phosphate) market is dominated by the pharmaceutical segment, which accounts for over 80% of the total market share. The pharmaceutical segment deals in developing, manufacturing, and marketing Tamiflu for human usage. It is the dominating sub-segment owing to high demand for Tamiflu usage to treat influenza during seasonal outbreaks and pandemics.
PEST Analysis
Political: Government authorities promote the usage of Tamiflu through public awareness campaigns during flu seasons and outbreaks to curb the spread of the influenza virus. Various regulations ensure the development and availability of effective Tamiflu drugs.
Economic: High healthcare expenditure on the treatment of influenza presents an opportunity for Tamiflu market growth. The economic burden of workplace absenteeism due to influenza further boosts the demand.
Social: Increasing awareness about the importance of early diagnosis and treatment of influenza through social media campaigns contributes to the market size expansion.
Technological: Advancements in drug delivery systems aid in developing modifications of Tamiflu with improved efficacy, safety, and convenience of usage. Continuous R&D leads to the discovery of novel ant-viral therapies.
Key Takeaways
The Global Tamiflu (Oseltamivir Phosphate) Market Size is expected to witness high growth over the forecast period owing to rising prevalence of influenza worldwide. The global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030.
The Asia Pacific region accounts for over 35% share of the global Tamiflu market due to the large patient population affected by influenza annually. China holds the highest market share in the region due to a growing elderly population vulnerable to virus attacks. Additionally, improving healthcare infrastructure and increasing healthcare spending foster market growth.
Key players:
Key players operating in the Tamiflu (Oseltamivir Phosphate) market are Hoffman La Roche, Amneal Pharmaceuticals, lnc., Sandoz, and Teva Pharmaceutical lndustries Ltd. Hoffman La Roche is the leading player with over 60% market share attributed to its well-established brand presence for Tamiflu globally.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
